These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31439369)

  • 21. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
    Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
    Han B; Suleman K; Wang L; Siddiqui J; Sercia L; Magi-Galluzzi C; Palanisamy N; Chinnaiyan AM; Zhou M; Shah RB
    Am J Surg Pathol; 2010 Apr; 34(4):478-85. PubMed ID: 20220513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
    Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJ
    Eur J Cancer; 2016 Oct; 66():26-33. PubMed ID: 27522247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.
    Guo CC; Epstein JI
    Mod Pathol; 2006 Dec; 19(12):1528-35. PubMed ID: 16980940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.
    Wissing M; Brimo F; Chevalier S; Scarlata E; McKercher G; O'Flaherty A; Aprikian S; Thibodeau V; Saad F; Carmel M; Lacombe L; Têtu B; Ekindi-Ndongo N; Latour M; Trudel D; Aprikian A
    BJU Int; 2019 Apr; 123(4):624-631. PubMed ID: 30113732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic potential to regional lymph nodes with Gleason score ≤7, including tertiary pattern 5, at radical prostatectomy.
    Diolombi ML; Epstein JI
    BJU Int; 2017 Jun; 119(6):872-878. PubMed ID: 27496532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
    Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
    Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.
    Rijstenberg LL; Hansum T; Hollemans E; Kweldam CF; Kümmerlin IP; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJLH
    Histopathology; 2020 Nov; 77(5):742-748. PubMed ID: 32542746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.
    Kato M; Hirakawa A; Sato H; Hanazawa R; Naito Y; Tochigi K; Sano T; Ishida S; Funahashi Y; Fujita T; Matsukawa Y; Hattori R; Tsuzuki T
    Int J Clin Oncol; 2021 Apr; 26(4):764-769. PubMed ID: 33385274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies.
    Shah RB; Magi-Galluzzi C; Han B; Zhou M
    Am J Surg Pathol; 2010 Apr; 34(4):470-7. PubMed ID: 20182345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(5):2518-26. PubMed ID: 24966964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
    Shah RB; Yoon J; Liu G; Tian W
    Histopathology; 2017 Nov; 71(5):693-702. PubMed ID: 28570007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients.
    Majewski W; Lange D; Stanek-Widera A; Itrych B; Krzysztofiak T; Jarząb M; Oczko-Wojciechowska M; Kajor M; Tarnawski R
    Pol J Pathol; 2022; 73(1):27-33. PubMed ID: 35848478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
    Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
    Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inter-observer variability of cribriform architecture and percent Gleason pattern 4 in prostate cancer: relation to clinical outcome.
    van der Slot MA; Hollemans E; den Bakker MA; Hoedemaeker R; Kliffen M; Budel LM; Goemaere NNT; van Leenders GJLH
    Virchows Arch; 2021 Feb; 478(2):249-256. PubMed ID: 32815034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer.
    Bernardino RM; Sayyid RK; Lajkosz K; Al-Daqqaq Z; Cockburn JG; Chavarriaga J; Abedi S; Leão R; Berlin A; van der Kwast T; Fleshner NE
    Eur Urol Focus; 2024 Jan; 10(1):146-153. PubMed ID: 37696743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.